295 related articles for article (PubMed ID: 21076471)
21. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of two new monoclonal antibodies against the CD34 molecule.
Barrande C; Traore Y; Szekeres G; Hirn J
Hybridoma; 1993 Apr; 12(2):203-13. PubMed ID: 7686138
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
24. [Expression and Clinical Significance of Leukemia Stem Cell Antigen in Acute Myeloid Leukemia].
Yao DD; Han BQ; Han YF; Zhang YQ; Jin YL; Dai HB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1583-1588. PubMed ID: 30501688
[TBL] [Abstract][Full Text] [Related]
25. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
[TBL] [Abstract][Full Text] [Related]
26. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
Andreasen RB; Olsson L
J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
[TBL] [Abstract][Full Text] [Related]
27. A new therapeutic target for leukemia comes to the surface.
Ritchie DS; Smyth MJ
Cell; 2009 Jul; 138(2):226-8. PubMed ID: 19632173
[TBL] [Abstract][Full Text] [Related]
28. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
Mohseni Nodehi S; Repp R; Kellner C; Bräutigam J; Staudinger M; Schub N; Peipp M; Gramatzki M; Humpe A
PLoS One; 2012; 7(8):e42426. PubMed ID: 22879978
[TBL] [Abstract][Full Text] [Related]
29. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
Hosen N; Park CY; Tatsumi N; Oji Y; Sugiyama H; Gramatzki M; Krensky AM; Weissman IL
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11008-13. PubMed ID: 17576927
[TBL] [Abstract][Full Text] [Related]
30. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia.
Gramatzki M; Ludwig WD; Burger R; Moos P; Rohwer P; Grünert C; Sendler A; Kalden JR; Andreesen R; Henschke F; Moldenhauer G
Exp Hematol; 1998 Dec; 26(13):1209-14. PubMed ID: 9845376
[TBL] [Abstract][Full Text] [Related]
31. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.
Wang Y; Yin C; Feng L; Wang C; Sheng G
Genet Mol Res; 2015 May; 14(2):5630-41. PubMed ID: 26125761
[TBL] [Abstract][Full Text] [Related]
32. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
33. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches.
Annaloro C; Onida F; Saporiti G; Lambertenghi Deliliers G
Curr Pharm Biotechnol; 2011 Feb; 12(2):217-25. PubMed ID: 21044004
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in acute myeloid leukemia.
Grosso DA; Hess RC; Weiss MA
Cancer; 2015 Aug; 121(16):2689-704. PubMed ID: 26095886
[TBL] [Abstract][Full Text] [Related]
35. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.
Anguille S; Van Tendeloo VF; Berneman ZN
Leukemia; 2012 Oct; 26(10):2186-96. PubMed ID: 22652755
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.
Strassberger V; Gutbrodt KL; Krall N; Roesli C; Takizawa H; Manz MG; Fugmann T; Neri D
J Proteomics; 2014 Mar; 99():138-51. PubMed ID: 24487095
[TBL] [Abstract][Full Text] [Related]
37. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).
Mitchell K; Steidl U
Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31451539
[TBL] [Abstract][Full Text] [Related]
38. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.
Hoang VT; Zepeda-Moreno A; Ho AD
Biotechnol J; 2012 Jun; 7(6):779-88. PubMed ID: 22588704
[TBL] [Abstract][Full Text] [Related]
39. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
40. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
